Workflow
Bragar Eagel & Squire is Investigating Certain Officers and Directors of Driven Brands and Jasper Therapeutics on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
Globenewswire· 2025-11-23 04:49
NEW YORK, Nov. 22, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating certain officers and directors Driven Brands Holdings, Inc. (NASDAQ: DRVN) and Jasper Therapeutics, Inc (NASDAQ:JSPR) on behalf of long-term stockholders. More information about each potential case can be found at the link provided. Driven Brands Holdings, Inc. (NASDAQ:DRVN) Bragar Eagel & Squire is investigating certain officers and directors of Driven Brands Holdin ...
Stellus Capital: Q3 Reveals That Distributions Continue To Exceed Earnings
Seeking Alpha· 2025-11-23 04:29
Core Insights - The article emphasizes the importance of a hybrid investment strategy that combines classic dividend growth stocks with Business Development Companies, REITs, and Closed End Funds to enhance investment income while achieving total returns comparable to traditional index funds [1]. Group 1: Investment Strategy - The company advocates for a diversified approach to investing, focusing on high-quality dividend stocks that provide long-term growth potential [1]. - A hybrid system is proposed, blending growth and income strategies to optimize investment returns [1]. - The total return achieved through this strategy is reported to be on par with the S&P index, indicating its effectiveness [1].
CSPC PHARMACEUTICAL(1093.HK):BD CONTINUES TO DRIVE LONG-TERM GROWTH
Ge Long Hui· 2025-11-23 04:16
Group 1: Financial Performance - CSPC reported total revenue of RMB19.9 billion for 9M25, with core revenue (excluding business development income) at RMB18.4 billion, down 19% YoY, representing 73.4% of the prior FY25 forecast [1] - Core revenue returned to sequential growth in 3Q25, increasing 4.2% QoQ, with modest growth observed across key therapeutic areas including neurology, oncology, anti-infectives, and cardiovascular products [1] - Attributable net profit for 9M25 was RMB3.5 billion, reflecting a 7.1% YoY decline [1] Group 2: Business Development and Licensing - CSPC has signed six out-licensing agreements since late 2024, covering a diverse portfolio of assets, indicating a sustainable out-licensing income stream [2] - The company anticipates further out-licensing of its EGFR ADC and a technology platform, although the timing of these deals remains uncertain [2] - CSPC is positioned to generate a sustainable and recurring stream of business development income over the medium to long term due to its diverse pipeline [2] Group 3: Pipeline and Clinical Development - Data readouts for the EGFR ADC (SYS6010) are expected in 1H26, with multiple pivotal trials underway in both China and the US [3] - Early data for SYS6010 monotherapy have shown promising activity in heavily pretreated patients, indicating high potential for out-licensing as data matures [3] - CSPC is preparing to launch two global Phase 3 trials targeting specific NSCLC patient populations, further enhancing its clinical development strategy [3] Group 4: Investment Outlook - CSPC's business development deals are seen as a key sustainable driver of earnings growth, leading to a revision of the target price from HK$12.11 to HK$11.05 [4] - The uncertain drug sales outlook for 2026 is a consideration in the revised target price [4]
MasTec Stock: Positive Q3, Strong Backlog And Future Growth Potential (NYSE:MTZ)
Seeking Alpha· 2025-11-23 04:14
David focuses on growth & momentum stocks that are reasonably priced and likely to outperform the market over the long-term. He is a long term investor of quality stocks and uses options for strategy. David told investors to buy in March 2009 at the bottom of the financial crisis. The S&P 500 increased 367% and the Nasdaq increased 685% from 2009 through 2019. He wants to help make people money by investing in high-quality growth stocks.Analyst’s Disclosure:I/we have no stock, option or similar derivative p ...
MasTec: Positive Q3, Strong Backlog And Future Growth Potential
Seeking Alpha· 2025-11-23 04:14
Core Insights - The focus is on growth and momentum stocks that are reasonably priced and expected to outperform the market in the long term [1] - The S&P 500 and Nasdaq saw significant increases of 367% and 685% respectively from 2009 to 2019, following a recommendation to buy at the financial crisis bottom in March 2009 [1] - The aim is to assist investors in making money through investments in high-quality growth stocks [1] Investment Strategy - The investment strategy involves long-term investment in quality stocks and the use of options [1] - Emphasis is placed on identifying high-quality growth stocks that are likely to yield substantial returns over time [1] Market Performance - The article highlights the substantial market recovery post-financial crisis, indicating a strong performance of major indices [1]
Why I Still Wouldn't Buy Palantir Stock -- Even After Its Recent Sell-Off
The Motley Fool· 2025-11-23 04:11
Core Viewpoint - Palantir Technologies has experienced a significant pullback in its stock price, which raises questions about its high valuation in a competitive AI software market [1][2][9] Company Performance - Palantir's third-quarter revenue grew 63% year over year to $1.18 billion, with U.S. revenue increasing by 77% and U.S. commercial revenue surging 121% [3] - Management has raised its fourth-quarter revenue growth expectation to about 61% year over year and lifted its full-year 2025 revenue outlook to approximately 53% growth, alongside strong adjusted free cash flow projections of $1.9 billion to $2.1 billion [4][10] Competitive Landscape - The AI software market is crowded, with competitors like Snowflake and Databricks aggressively investing in AI, and large cloud providers like Microsoft and Amazon having structural advantages [6][7] - Palantir remains a smaller player with fewer resources and a significant portion of its revenue still tied to government contracts, which can be unpredictable [8] Valuation Concerns - Despite strong growth and profitability, Palantir's valuation is considered extremely high, with a forward price-to-earnings ratio exceeding 165, which may not provide a margin of safety if AI spending normalizes [9][11] - The stock's current price reflects expectations of exceptional growth and strong economics, making it potentially risky for investors [12]
Griffon Corporation Stock: The Door To Upside Hasn't Shut Yet (NYSE:GFF)
Seeking Alpha· 2025-11-23 03:59
Core Insights - Crude Value Insights provides an investment service and community focused on the oil and natural gas sectors, emphasizing cash flow and the companies that generate it, which leads to value and growth prospects with real potential [1] - Subscribers have access to a model account with over 50 stocks, in-depth cash flow analyses of exploration and production (E&P) firms, and live chat discussions about the sector [1] Subscription Offer - A two-week free trial is available for new subscribers, allowing them to explore the services related to oil and gas investments [2]
Boise Cascade: Not Just Another Cyclical, But Not Undervalued (NYSE:BCC)
Seeking Alpha· 2025-11-23 03:45
Boise Cascade LLC ( BCC ) is an American, integrated forest products company. Their origins date back to separate companies in the early 1900s, which merged in 1957 to become Boise Cascade. This was a sprawling conglomerate, and from 2004-2008, they divested $3.7I am an independent analyst and investor interested in investing at the intersection of value and growth. My method is a highly qualitative focus on mostly small caps, looking for both long term compounders as well as some special situations. On Twi ...
Geospace Technologies Stock: Dismal Quarter But Better Times Ahead - Hold (NASDAQ:GEOS)
Seeking Alpha· 2025-11-23 03:44
Group 1 - The analyst team has a proven track record of outperforming across all market conditions, achieving an annualized return of almost 40% over the past decade with a long-only model portfolio return of over 23 times [1] - The focus includes income-oriented picks for lower-risk firms with steady dividend payouts, indicating a strategy that caters to conservative investors [1] - The research covers the energy, shipping, and offshore markets, highlighting the firm's expertise in these sectors [1] Group 2 - The analyst has a historical focus on tech stocks but has expanded coverage to include the offshore drilling and supply industry, as well as the shipping industry, which encompasses tankers, containers, and dry bulk [2] - The analyst is also monitoring the emerging fuel cell industry, suggesting a forward-looking approach to investment opportunities [2] - The analyst's background includes experience as an auditor for PricewaterhouseCoopers and navigating significant market events such as the dotcom bubble and the subprime crisis [2]
Geospace Technologies: Dismal Quarter But Better Times Ahead - Hold (Rating Upgrade)
Seeking Alpha· 2025-11-23 03:44
Core Insights - The analyst team has demonstrated a strong track record, achieving an annualized return of almost 40% over the past decade, with a long-only model portfolio return exceeding 23 times [1]. Group 1: Investment Focus - The company offers income-focused investment options for those preferring lower-risk firms with consistent dividend payouts [1]. - The analyst has expanded coverage to include the offshore drilling and supply industry, as well as the shipping industry, which encompasses tankers, containers, and dry bulk [2]. Group 2: Analyst Background - The analyst has a background in auditing with PricewaterhouseCoopers and has transitioned to day trading for nearly 20 years, successfully navigating significant market events such as the dotcom bubble and the subprime crisis [2].